secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001213900-25-114763
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea reports Phase 1 partial response for PAS-004 in advanced cancer; ALS Association awards $1M grant
--------------------------------------------------------------------------------

- BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.
- Overall disease control rate 71.4% in BRAF-mutated tumors; no DLTs or discontinuations across 27 patients.
- PAS-004 tablet formulation shows 3-fold higher dose-normalized exposure vs capsule with less variability.
- Cohort 7 (37mg capsule): zero TRAEs in DLT period; 80% pERK inhibition at Cmax; SRC clears escalation to 45mg.
- ALS Association awards ~$1M grant for Phase 1 study of PAS-004 in 12 ALS patients (safety, ALSFRS-R, NfL).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025114763/0001213900-25-114763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025114763/ea0266606-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-114763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer